News

4SC-202 is a benzamide type selective inhibitor of human class I histone deacetylases (HDAC) isoenzymes 1, 2 and 3. TOPAS is a mono-centric, single arm, open-label dose escalation

5N Plus deploys a range of proprietary and technologies to produce products which are used in a number of pharmaceutical, electronic and industrial applications. Following the acquisition, MCP

The company has submitted the application on the basis of positive results which it has witnessed form preclinical studies. The studies showed Alliqua’s hydrogel based patch technology successfully

Previously, Dimerix signed an agreement with Takeda on 15 April 2010. As per the terms of the agreement, Dimerix will continue using its GPCR-HIT platform and insights into

Nyloxin is indicted for the treatment of moderate to severe (Stage 2) chronic pain. Currently, Nyloxin is available in the US as an oral spray for treating back

As per the agreement, both the companies will jointly work and organize research for the discovery of DDS technology for RNAi therapeutics based on Samyang’s technology in three

The FDA has informed Perrigo that, effective immediately, the company has an acceptable regulatory status, such that any pending export license and ANDA applications from this facility will

Afinitor tablets are indicated for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. ODAC has recommended the drug on the basis of Phase III

Medline manufactures and distributes healthcare products to more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies. Companies manage their physical and